

August 26, 2022

The Honorable Patrick Leahy
Chair
Committee on Appropriations
United States Senate
Washington, DC 20510

The Honorable Patty Murray
Chair
LHHS Subcommittee
Committee on Appropriations
United States Senate
Washington, DC 20510

The Honorable Chris Coons
Chair
State and Foreign Operations Subcommittee
Committee on Appropriations
United States Senate
Washington, DC 20510

The Honorable Richard Shelby
Ranking Member
Committee on Appropriations
United States Senate
Washington, DC 20510

The Honorable Roy Blunt
Ranking Member
LHHS Subcommittee
Committee on Appropriations
United States Senate
Washington, DC 20510

The Honorable Lindsay Graham
Ranking Member
State and Foreign Operations Subcommittee
Committee on Appropriations
United States Senate
Washington, DC 20510

Subject: Infectious Diseases Programs in FY2023 Appropriations Bills

Dear Chairwoman Leahy Ranking Member Shelby, Chairwoman Murray, Ranking Member Blunt, Chairman Coons, Ranking Member Graham,

On behalf of the Infectious Diseases Society of America (IDSA) and our 12,000 members, thank you for your leadership in providing increased FY2023 funding in the released Labor, Health, and Human Services (LHHS) and State and Foreign Operations (SFOPs) appropriations bills for domestic and global infectious diseases (ID) programs necessary to protect public health; prevent, prepare for and respond to outbreaks and other emergencies; spur biomedical research; and support early career ID scientists. We particularly appreciate the increased investments in the federal response to antimicrobial resistance (AMR) and the support for a novel subscription model for incentivizing antibiotic research and development conveyed in the LHHS explanatory statement.

IDSA members care for patients with serious infections, including influenza, HIV/AIDS, tuberculosis, viral hepatitis, infections associated with opioid use, infections associated with cancer and transplantation, as well as infections that are resistant to available antimicrobials. We are on the frontlines of the COVID-19 pandemic and the monkeypox outbreak.

Increased AMR funding in the released Senate Appropriations bills are critical to bolster AMR surveillance and prevention, improve antimicrobial stewardship, expand AMR research and strengthen the antibiotic pipeline. Key investments include \$212 million for the Antibiotic



2021-2022 BOARD OF DIRECTORS

President
Daniel P. McQuillen, M.D., FIDSA
BETH ISRAEL LAHEY HEALTH
LAHEY HOSPITAL & MEDICAL CENTER
BURLINGTON, MA

President-Elect
Carlos Del Rio, M.D., FIDSA
EMORY SCHOOL OF MEDICINE AT
GRADY HEALTH SYSTEM
ATLANTA, GA

Vice President
Steven K. Schmitt, M.D., FIDSA
CLEVELAND CLINIC
CLEVELAND, OH

Secretary
Angela M. Caliendo, M.D., Ph.D., FIDSA
ALPERT MEDICAL SCHOOL OF BROWN UNIVERSITY
RHODE ISLAND HOSPITAL
PROVIDENCE, RI

Treasurer
Jeanne Marrazzo, M.D., MPH, FIDSA
UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
BIRMINGHAM, AL

Immediate Past President
Barbara D. Alexander, M.D., MHS, FIDSA
DUKE UNIVERSITY
DURHAM, NC

Lilian M. Abbo, M.D., FIDSA
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
MIAMI, FL

Adaora A. Adimora, M.D., MPH, FIDSA
UNIVERSITY OF NORTH CAROLINA SCHOOL
OF MEDICINE
CHAPEL HILL, NC

Cesar A. Arias, M.D., Ph.D., FIDSA
HOUSTON METHODIST HOSPITAL
HOUSTON, TX

Wendy Armstrong, M.D., FIDSA
EMORY UNIVERSITY
ATLANTA, GA

Maximo O. Brito, M.D., MPH, FIDSA
UNIVERSITY OF ILLINOIS AT CHICAGO
CHICAGO, IL

Rana Chakraborty, M.D., MSc, D.Phil., FIDSA
MAYO CLINIC
ROCHESTER, MN

Kimberly E. Hanson, M.D., FIDSA
UNIVERSITY OF UTAH
SALT LAKE CITY, UT

John B. Lynch, III, M.D., MPH, FIDSA
HARBORVIEW MEDICAL CENTER
UNIVERSITY OF WASHINGTON
SEATTLE, WA

Jasmine R. Marcelin, M.D., FIDSA
UNIVERSITY OF NEBRASKA MEDICAL CENTER
OMAHA, NE

Chief Executive Officer
Christopher D. Busky, CAE

IDSA Headquarters
4040 Wilson Boulevard
Suite 300
Arlington, VA 22203
TEL: (703) 299-0200
FAX: (703) 299-0204
EMAIL ADDRESS:
info@idsociety.org
WEBSITE:
www.idsociety.org

Resistance Solutions Initiative at the Centers for Disease Control and Prevention, \$818 million in overall funding for the Biomedical Advance Research and Development Authority, and \$6.449 billion for the National Institute of Allergy and Infectious Diseases, including \$565 million for AMR research. Additionally, we appreciate increased funding for other vital domestic and global ID programs., including those listed below.

Thank you for the attention given to infectious diseases in the Senate FY2023 appropriations bills released by the full committee. We look forward to working with you to realize increased investments to combat infectious diseases, especially AMR, by passing a final FY2023 appropriations bill. If we can serve as a resource for your efforts, please have your staff contact Lisa Cox, IDSA Director of Government Relations, at lcox@idsociety.org.

Sincerely,

A handwritten signature in black ink, appearing to read 'D. McQuillen', written over a circular stamp or seal.

Daniel P. McQuillen, MD, FIDSA
President, Infectious Diseases Society of America

Labor, Health and Human Services Appropriations Bill

- \$212 million for the **CDC's Antibiotic Resistance Solutions Initiative**, a \$30 million increase over FY2022;
- \$31 million in funding for the **National Healthcare Safety Network at CDC**, a \$10 million increase over FY2022;
- \$50 million in funding for the **Advanced Molecular Detection initiative at CDC**, a \$15 million increase over FY2022;
- \$760 million in funding, an increase of \$114 million above FY 2022, for the **CDC's Center for Global Health**. This includes \$353 million for global health security, a \$100 million increase;
- \$818 million for the **Biomedical Advanced Research and Development Authority**, a \$73.5 million increase over FY 2022 funding; and,
- \$6.449 billion for the **National Institute of Allergy and Infectious Diseases at the National Institutes of Health**, a \$127 million increase over FY 2022, including \$565 million for antibiotic resistance research at NIAID, an increase of \$25 million over FY 2022;

State and Foreign Operations Appropriations Bill

- \$745 million for global health security focused on pandemic prevention, detection and response, an increase of \$45 million above the FY 2022 enacted level;
- \$2 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria, a \$440 million increase to support a strong U.S. commitment to the seventh replenishment of the Global Fund in support of the goal of ending the epidemics of HIV, TB and malaria;
- \$4.37 billion for the President's Emergency Plan for AIDS Relief, a \$20 million cut over the FY 2022 enacted level; and
- \$400 million for the USAID global TB program, a \$28.95 million increase.